IBM-Renal: Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques

Sponsor
University of Cambridge (Other)
Overall Status
Recruiting
CT.gov ID
NCT06016075
Collaborator
(none)
30
1
3
24
1.2

Study Details

Study Description

Brief Summary

The aim of this study is to develop techniques for non-invasive imaging of biology in participants with benign or malignant renal masses based on the novel scanning MRI techniques, including recently invented Hyperpolarised MRI, deuterium metabolic imaging and sodium MRI. This imaging study will: 1) acquire imaging data from human tissues following the injection of hyperpolarised 13C pyruvate and use 13C-MRI to monitor changes in the ratio of 13C-lactate to 13C-pyruvate; 2) acquire imaging data from human tissues using Sodium MRI or 3) acquire imaging data from human tissues following the oral consumable of deuterated glucose. Data acquired during this physiological study will be used to optimise future imaging protocols.In the UK and possibly in other countries, there are some patients with renal masses that are over treated or undergo unnecessary procedures such as surgery or biopsies, as they are thought to have a malignant tumour or a more aggressive tumour but after the procedure it is found that the mass was benign. The aim of this study is to determine whether one or all of these imaging techniques can differentiate between benign and malignant renal masses with the view to developing the techniques further and hopefully reducing the need for over treatment or unnecessary procedures in patients with benign masses.

Condition or Disease Intervention/Treatment Phase
  • Device: Magnetic Resonance Imaging
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Hyperpolarised MRI

Device: Magnetic Resonance Imaging
Novel MRI techniques

Other: Sodium MRI

Device: Magnetic Resonance Imaging
Novel MRI techniques

Other: DMI MRI

Device: Magnetic Resonance Imaging
Novel MRI techniques

Outcome Measures

Primary Outcome Measures

  1. LAC/PYR ratio [1 year]

    LAC/PYR ratio in renal tumours

  2. Total Sodium Concentration [1 year]

    Total Sodium Concentration - in renal tumours

  3. DMI - technical feasibility [1 year]

    DMI - technical feasibility in abdomen

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Over 18 years old

  • Able to and provide written informed consent to participate

  • If female, postmenopausal or if women of child bearing potential (WOCBP) using a suitable contraception

  • If male, using a suitable contraceptive method for the duration of the study

  • Radiologically suspected or pathologically confirmed benign or malignant renal masses, as determined by standard clinical practice

  • Capable of undergoing a minimum of one study visit

Exclusion Criteria:
  • Contraindication or inability to tolerate MRI

  • Pregnant or actively breast-feeding woman

  • If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI safe at 3 T (researcher to confirm)

  • Clinically significant cardiac, pulmonary or neurological diseases as determined by the investigators

  • Laboratory abnormalities that may impact on the study results

  • Any other significant medical or psychiatric history rendering the subject ineligible as deemed by the investigators

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Department of Radiology Cambridge Cambridgeshire United Kingdom CB2 0QQ

Sponsors and Collaborators

  • University of Cambridge

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ines Horvat-Menih, MD, University of Cambridge
ClinicalTrials.gov Identifier:
NCT06016075
Other Study ID Numbers:
  • Radiology, Uni of Cambridge
  • 22/EE/0136
  • 314155
First Posted:
Aug 29, 2023
Last Update Posted:
Aug 29, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 29, 2023